SMAD2 and dentin dysplasia: At week 3, in the losartan-treated animals, various experimental parameters improved as compared to that in the RT only group, such as several echocardiographic signs of LVH and consequential DD together with the overexpression of β-MHC and SMAD2/3 in the left ventricle indicating a possible anti-hypertrophic and anti-fibrotic effect of losartan in the early chronic phase of RIHD.